Literature DB >> 21729965

Implanon® failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.

E J McCarty1, H Keane, K Quinn, S Quah.   

Abstract

Since its introduction in 1999, Implanon® remains one of the preferred contraceptive choices for many women as it offers a highly effective means of long-term contraception for three years that does not rely on adherence. Like all hormonal contraceptives, certain hepatic enzyme-inducing drugs may reduce its efficacy. We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21729965     DOI: 10.1258/ijsa.2009.009469

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  12 in total

1.  Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.

Authors:  Megan Neary; Catherine A Chappell; Kimberly K Scarsi; Shadia Nakalema; Joshua Matovu; Sharon L Achilles; Beatrice A Chen; Marco Siccardi; Andrew Owen; Mohammed Lamorde
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

2.  Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.

Authors:  Catherine A Chappell; Mohammed Lamorde; Shadia Nakalema; Beatrice A Chen; Hope Mackline; Sharon A Riddler; Susan E Cohn; Kristin M Darin; Sharon L Achilles; Kimberly K Scarsi
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

Review 3.  Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.

Authors:  Andrea R Thurman; Sharon Anderson; Gustavo F Doncel
Journal:  Am J Reprod Immunol       Date:  2014-02-13       Impact factor: 3.886

4.  Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy.

Authors:  Maria Pyra; Renee Heffron; Nelly R Mugo; Kavita Nanda; Katherine K Thomas; Connie Celum; Athena P Kourtis; Edwin Were; Helen Rees; Elizabeth Bukusi; Jared M Baeten
Journal:  AIDS       Date:  2015-11       Impact factor: 4.177

5.  Contraceptive use among HIV-infected women and men receiving antiretroviral therapy in Lusaka, Zambia: a cross-sectional survey.

Authors:  Nancy L Hancock; Carla J Chibwesha; Samuel Bosomprah; Jonathan Newman; Mwangelwa Mubiana-Mbewe; Elizabeth Siyama Sitali; Carolyn Bolton-Moore; Clara Mbwili-Muleya; Benjamin H Chi
Journal:  BMC Public Health       Date:  2016-05-12       Impact factor: 3.295

Review 6.  Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.

Authors:  Rena C Patel; Chelsea Morroni; Kimberly K Scarsi; Tabitha Sripipatana; James Kiarie; Craig R Cohen
Journal:  J Int AIDS Soc       Date:  2017-05-11       Impact factor: 5.396

7.  Effect of concurrent use of anti-retroviral therapy and levonorgestrel sub-dermal implant for contraception on CD4 counts: a prospective cohort study in Kenya.

Authors:  David Hubacher; Jennifer Liku; James Kiarie; Joel Rakwar; Peter Muiruri; Jackline Omwenga; Pai-Lien Chen
Journal:  J Int AIDS Soc       Date:  2013-03-01       Impact factor: 5.396

Review 8.  Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy.

Authors:  Jennifer A Robinson; Roxanne Jamshidi; Anne E Burke
Journal:  Infect Dis Obstet Gynecol       Date:  2012-08-14

Review 9.  Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.

Authors:  Rena C Patel; Maricianah Onono; Monica Gandhi; Cinthia Blat; Jill Hagey; Starley B Shade; Eric Vittinghoff; Elizabeth A Bukusi; Sara J Newmann; Craig R Cohen
Journal:  Lancet HIV       Date:  2015-10-22       Impact factor: 12.767

10.  Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.

Authors:  Kimberly K Scarsi; Kristin M Darin; Shadia Nakalema; David J Back; Pauline Byakika-Kibwika; Laura J Else; Sujan Dilly Penchala; Allan Buzibye; Susan E Cohn; Concepta Merry; Mohammed Lamorde
Journal:  Clin Infect Dis       Date:  2015-12-08       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.